These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 35477432)

  • 1. Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial).
    Yang Z; Zhang X; Zhang J; Gao J; Bai Z; Deng W; Chen G; An Y; Liu Y; Wei Q; Han J; Li A; Liu G; Sun Y; Kong D; Yao H; Zhang Z
    BMC Cancer; 2022 Apr; 22(1):462. PubMed ID: 35477432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy].
    Wang XH; Zhou CJ; Zhang S; Wang QX; Xiao WW; Ding PR; Chen G; Pan ZZ; Zeng ZF; Gao YH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):266-273. PubMed ID: 32192306
    [No Abstract]   [Full Text] [Related]  

  • 3. Short-course radiotherapy combined with CAPOX and Toripalimab for the total neoadjuvant therapy of locally advanced rectal cancer: a randomized, prospective, multicentre, double-arm, phase II trial (TORCH).
    Wang Y; Shen L; Wan J; Zhang H; Wu R; Wang J; Wang Y; Xu Y; Cai S; Zhang Z; Xia F
    BMC Cancer; 2022 Mar; 22(1):274. PubMed ID: 35291966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial.
    Liu S; Wang X; Zhuang Y; Bai S; Wu X; Ye Y; Luo H; Yu H; Wang Q; Chang H; Zeng Z; Cai P; Pan Z; Gao Y; Chen G; Xiao W
    Cancer Med; 2023 Jun; 12(12):13352-13360. PubMed ID: 37156624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma.
    Shamseddine A; Zeidan YH; Kreidieh M; Khalifeh I; Turfa R; Kattan J; Mukherji D; Temraz S; Alqasem K; Amarin R; Al Awabdeh T; Deeba S; Jamali F; Mohamad I; Elkhaldi M; Daoud F; Al Masri M; Dabous A; Hushki A; Jaber O; Khoury C; El Husseini Z; Charafeddine M; Al Darazi M; Geara F
    BMC Cancer; 2020 Sep; 20(1):831. PubMed ID: 32873251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
    Shamseddine A; Zeidan YH; El Husseini Z; Kreidieh M; Al Darazi M; Turfa R; Kattan J; Khalifeh I; Mukherji D; Temraz S; Alqasem K; Amarin R; Al Awabdeh T; Deeba S; Jamali F; Mohamad I; Elkhaldi M; Daoud F; Al Masri M; Dabous A; Hushki A; Jaber O; Charafeddine M; Geara F
    Radiat Oncol; 2020 Oct; 15(1):233. PubMed ID: 33028346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancer.
    Gao J; Zhang X; Yang Z; Zhang J; Bai Z; Deng W; Chen G; Xu R; Wei Q; Liu Y; Han J; Li A; Liu G; Sun Y; Kong D; Yao H; Zhang Z
    Front Oncol; 2023; 13():1057947. PubMed ID: 36816939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total neoadjuvant therapy with short-course radiotherapy Versus long-course neoadjuvant chemoradiotherapy in Locally Advanced Rectal cancer, Korean trial (TV-LARK trial): study protocol of a multicentre randomized controlled trial.
    Kim MJ; Lee DW; Kang HC; Park JW; Ryoo SB; Han SW; Kim KS; Chie EK; Oh JH; Jeong WK; Kim BH; Nam EM; Jeong SY
    BMC Cancer; 2023 Aug; 23(1):734. PubMed ID: 37553666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
    Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
    [No Abstract]   [Full Text] [Related]  

  • 10. Non-operative management after chemoradiotherapy plus consolidation or sandwich (induction with bevacizumab and consolidation) chemotherapy in patients with locally advanced rectal cancer: a multicentre, randomised phase II trial (NOMINATE trial).
    Akiyoshi T; Shinozaki E; Taguchi S; Chino A; Hiratsuka M; Tominaga T; Nonaka T; Toda S; Matoba S; Matsui S; Okabayashi K; Mukai T; Hiyoshi Y; Yamaguchi T; Nagasaki T; Yamaguchi K; Ueno M; Kuroyanagi H; Fukunaga Y; Ishizuka N; Konishi T;
    BMJ Open; 2022 Mar; 12(3):e055140. PubMed ID: 35304396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Short-course radiotherapy combined with CAPOX and PD-1 inhibitor for the total neoadjuvant therapy of locally advanced rectal cancer: the preliminary single-center findings of a prospective, multicentre, randomized phase II trial (TORCH)].
    Wang YQ; Shen LJ; Wan JF; Zhang H; Wang Y; Wu X; Wang JW; Wang RJ; Sun YQ; Tong T; Huang D; Wang L; Sheng WQ; Zhang X; Cai GX; Xu Y; Cai SJ; Zhang Z; Xia F
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):448-458. PubMed ID: 37217353
    [No Abstract]   [Full Text] [Related]  

  • 12. Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT).
    van den Berg K; Schaap DP; Voogt ELK; Buffart TE; Verheul HMW; de Groot JWB; Verhoef C; Melenhorst J; Roodhart JML; de Wilt JHW; van Westreenen HL; Aalbers AGJ; van 't Veer M; Marijnen CAM; Vincent J; Simkens LHJ; Peters NAJB; Berbée M; Werter IM; Snaebjornsson P; Peulen HMU; van Lijnschoten IG; Roef MJ; Nieuwenhuijzen GAP; Bloemen JG; Willems JMWE; Creemers GJM; Nederend J; Rutten HJT; Burger JWA
    BMC Cancer; 2022 Sep; 22(1):957. PubMed ID: 36068495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
    Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
    BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
    Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB
    Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 16. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
    Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
    Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase III Trial.
    Mei WJ; Wang XZ; Li YF; Sun YM; Yang CK; Lin JZ; Wu ZG; Zhang R; Wang W; Li Y; Zhuang YZ; Lei J; Wan XB; Ren YK; Cheng Y; Li WL; Wang ZQ; Xu DB; Mo XW; Ju HX; Ye SW; Zhao JL; Zhang H; Gao YH; Zeng ZF; Xiao WW; Zhang XP; Zhang X; Xie E; Feng YF; Tang JH; Wu XJ; Chen G; Li LR; Lu ZH; Wan DS; Bei JX; Pan ZZ; Ding PR
    Ann Surg; 2023 Apr; 277(4):557-564. PubMed ID: 36538627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-course chemoradiation plus concurrent/sequential PD-1 blockade as neoadjuvant treatment for MMR-status-unscreened locally advanced rectal cancer: protocol of a multicentre, phase 2, randomised controlled trial (the POLAR-STAR trial).
    Pang K; Yang Y; Tian D; Zeng N; Cao S; Ling S; Gao J; Zhao P; Wang H; Kong Y; Zhang J; Chen G; Deng W; Bai Z; Jin L; Wu G; Zhu D; Wang Y; Zhou J; Wu B; Lin G; Xiao Y; Gao Z; Ye Y; Wang X; Li A; Han J; Yao H; Yang Y; Zhang Z
    BMJ Open; 2023 Sep; 13(9):e069499. PubMed ID: 37699634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining chemotherapy and tislelizumab with preoperative split-course hypofraction radiotherapy for locally advanced rectal cancer: study protocol of a prospective, single-arm, phase II trial.
    Zheng R; Wang BS; Li Z; Chi P; Xu B
    BMJ Open; 2023 Mar; 13(3):e066976. PubMed ID: 36927585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
    Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.